TABLE A1.
Subgroup Analysis on the Basis of MET Amplification, Liver Metastases, Brain Metastases, and Age
| Variable | MET Amplification+ (n = 12) | MET Amplification– (n = 40) | With Liver Metastases (n = 6) | With Brain Metastases (n = 5) | ≥75 Years (n = 21) |
|---|---|---|---|---|---|
| Objective response rate, % | 12 (100.0) | 27 (67.5) | 4 (66.7) | 5 (100.0) | 18 (85.7) |
| 95% CI | 73.5 to 100.0 | 50.9 to 81.4 | 22.3 to 95.7 | 47.8 to 100.0 | 63.7 to 97.0 |
| Disease control rate, % | 12 (100.0) | 38 (95.0) | 6 (100.0) | 5 (100.0) | 20 (95.2) |
| 95% CI | 73.5 to 100.0 | 83.1 to 99.4 | 54.1 to 100.0 | 47.8 to 100.0 | 76.2 to 99.9 |
| Duration of response, median, months (95% CI) |
13.5 (3.7 to NE) | 15.9 (9.2 to 19.1) | 9.2 (5.5 to NE) | 5.6 (3.7 to NE) | 19.1 (9.2 to NE) |
| 6-month PFS rate (95% CI) | 66.7 (33.7 to 86.0) | 73.3 (53.7 to 85.7) | 75.0 (12.8 to 96.1) | 40.0 (5.2,75.3) | 78.9 (53.2 to 91.5) |
| 12-month PFS rate (95% CI) | 57.1 (25.4 to 79.6) | 56.5 (37.1 to 72.0) | 25.0 (0.9 to 66.5) | 20.0 (0.8 to 58.2) | 68.4 (42.8 to 84.4) |
| PFS, median, months (95% CI) | 14.4 (4.7 to NE) | 13.1 (6.3 to 17.9) | 8.2 (2.8 to NE) | 6.4 (4.5 to NE) | 18.2 (6.3 to NE) |
| OS, months, median (95% CI) | NR (13.7 to NE) | 20.3 (15.2 to NE) | 14.5 (3.7 to NE) | 17.9 (4.5 to NE) | NR (14.4 to NE) |
Abbreviations: NE, not estimated; NR, not reached; OS, overall survival; PFS, progression-free survival.